Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology.
Adolescent
Adult
Aged
Aged, 80 and over
Ascitic Fluid
/ chemistry
Biomarkers, Tumor
/ analysis
Biopsy, Fine-Needle
/ methods
Carcinoma, Ovarian Epithelial
/ diagnosis
Cystadenocarcinoma, Serous
/ diagnosis
Cytodiagnosis
/ methods
Female
Humans
Immunohistochemistry
Middle Aged
Retrospective Studies
Young Adult
Ascitic fluid
Fine-needle aspiration
High-grade serous carcinoma ovary
NACT
Neoadjuvant chemotherapy
Ovarian carcinoma
Journal
American journal of clinical pathology
ISSN: 1943-7722
Titre abrégé: Am J Clin Pathol
Pays: England
ID NLM: 0370470
Informations de publication
Date de publication:
08 06 2020
08 06 2020
Historique:
pubmed:
10
4
2020
medline:
21
10
2020
entrez:
10
4
2020
Statut:
ppublish
Résumé
High-grade serous carcinoma (HGSC) is the most common ovarian malignancy. The role of cytopathology in obtaining tissue diagnosis before institution of neoadjuvant chemotherapy (NACT) was evaluated. All histopathology-proven HGSC specimens between 2015 and 2018 with prior cytopathologic diagnosis by ascitic fluid evaluation or fine-needle aspiration (FNA) of ovarian mass were reviewed with cell block immunocytochemistry for CK7, CK20, PAX8, WT1, and p53. Of 288 cases of HGSC, pre-NACT cytology diagnosis was established in 32% (93/288), with specific HGSC diagnoses made on ascitic fluid in 88% (82/93) and by ovarian mass FNA in 12% (11/93). The ascitic fluid showed moderate/high cellularity with papillary clusters in 76% (71/93) cases. Cell block immunocytochemistry showed tumor cells positive for CK7, PAX8, and WT1. p53 showed mutant or null-type positivity in 65% (33/51) and 33% (17/51) of cases, respectively, with 100% concordance with subsequent histopathology specimens. Poor/intermediate response to chemotherapy was shown in 75% of cases. Combined assessment of cytomorphology, cell block histomorphology, and ancillary immunohistochemical testing, including PAX8, WT1, and p53, allows for specific pre-NACT diagnoses of HGSC in ascitic fluid and ovarian FNA cytology. This practice allows for initiation of chemotherapy and diminution of disease burden prior to definitive surgical therapy.
Identifiants
pubmed: 32271370
pii: 5818395
doi: 10.1093/ajcp/aqaa028
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-114Informations de copyright
© American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.